A new study identifies how the molecule, called ApoM, can clear harmful cholesterol deposits linked to macular degeneration ...

Belite Bio has completed enrolment in the 24-month PHOENIX Phase III trial assessing the tolerability and safety of oral ...

Yesafili, a biosimilar to Eylea, received Health Canada's approval, marking the first such approval in Canada. Indicated for ...

D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment ...

Berlin: Bayer has received approval from the European Commission (EC) for a label extension in the European Union (EU) for ...

Landmark partnership will democratize access to critical eye treatment for millions facing preventable blindness from ...

The PHOENIX study is a 24-month, randomized, double-masked, placebo-controlled, multicenter, pivotal Phase 3 trial. The study is ongoing across sites in the United States, the United Kingdom, France, ...

Ocular Therapeutix is making sure its corporate vision is 20/20 as it looks forward to phase 3 data on its eye disease drug candidate Axpaxli. | Ocular Therapeutix is making sure its corporate vision ...

Career focused on driving business growth and developing an integrated commercial strategy to deliver results ...

The product is a corticosteroid indicated for the treatment of postoperative inflammation and pain following ocular surgery.

Cost-Efficient Methodology Aims To Reduce Reliance On Expensive Diagnostic Procedures Such As MRI, CT Scans, PET Scans, and Echocardiograms ...